Deal Watch: Pfizer, BioAtla Team Up To Develop Targeted Antibody Oncologics

ViroMed looks to bluebird to take its humanized antibody to the next steps of development in immuno-oncology. Takeda gets option for Cour's nanoparticle technology in Celiac disease, as well as up to three other indications.